Treatment of primary cutaneous B-cell lymphoma with rituximab
Authors:
- 1 May 2005
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 52 (5) , 847-853
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Diagnostic principles and new developments in primary cutaneous B-cell lymphomasJournal of Dermatological Science, 2004
- Therapy of Cutaneous Lymphoma – Current Practice and Future DevelopmentsOncology Research and Treatment, 2003
- Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximabJournal of Cancer Research and Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic StudyLeukemia & Lymphoma, 2002
- Systemic Therapy of Primary Cutaneous B-cell Lymphoma, Marginal Zone Type, with Rituximab, a Chimeric Anti-CD20 Monoclonal AntibodyActa Dermato-Venereologica, 2001
- Primary Cutaneous Large B-Cell Lymphoma of the LegsAmerican Journal of Clinical Oncology, 2001
- Intralesional rituximab for cutaneous B-cell lymphomaBritish Journal of Dermatology, 2001
- Der Anti-CD20-Antikörper bei primär kutanen B-Zell-LymphomenDie Dermatologie, 2001
- Die Therapie der primären kutanen B-Zell-LymphomeDie Dermatologie, 2000